Upjohn/Chemex
Executive Summary
Chemex is evaluating Upjohn's Trobicin (spectinomycin) and Cytosar-U (cytarabine) for development as dermatological antivirals to treat infections, warts, and acne, under an agreement announced Jan. 6. Chemex could begin clinicals "as early as April." Trobicin is marketed for gonorrhea; Cytosar-U is indicated for leukemia.